Alonso-Dominguez et al. provided evidence that high PTCH1 expression in mononuclear cells at diagnosis predicts imatinib failure in CP-CML and identifies a cohort of patients that may benefit from a second generation TKI as first-line therapy44. The gene discussed is PTCH1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.